Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRISH trial of low-dose peginterferon alfa-2a in compensated HCV cirrhosis with HIV coinfection
2006-006985-41Phase 3Active
- Sponsor
- JOAQUIN PORTILLA
- Start
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a in hepatitis C virus infection, Cirrhosis and human immunodeficiency virus infection (HIV) (2 arms), sponsored by JOAQUIN PORTILLA. Primary endpoint: Efficacy. Started Mar 2007; status: active.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C virus infectionCirrhosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-006985-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006985-41.